Suggestions
Omar Khwaja
Chief Medical Officer at VectivBio AG
Omar Khwaja is an experienced medical professional and drug developer who currently serves as the Chief Medical Officer at VectivBio AG, a clinical-stage biotechnology company focused on developing treatments for rare diseases.12
Professional Background
Dr. Khwaja has over two decades of experience in drug development, medicine, and academia.1 His career highlights include:
- Chief Medical Officer and Head of Research & Development at Voyager Therapeutics, a biotechnology company focused on severe neurological diseases12
- Global Head of Rare Diseases and Neuroscience Translational Medicine at Roche, where he worked for over eight years12
- Director of the Clinical Neurogenetics program at Boston Children's Hospital12
- Faculty member at Harvard Medical School12
Specializations
Dr. Khwaja is a pediatric neurologist with specialized skills in:
- Critical care
- Fetal-neonatal neurology
- Neurogenetics
- Clinical-translational research related to diseases of the developing brain and rare diseases4
Education and Qualifications
- M.D. and Ph.D. in Human Molecular Genetics from the University of Cambridge12
- Member of the Royal College of Physicians12
- Member of the Royal College of Paediatrics and Child Health34
Current Roles
In addition to his position at VectivBio AG, Dr. Khwaja also serves as:
- Chief Medical Officer for the Spinal Muscular Atrophy Foundation12
- Chair of the Scientific Advisory Board of the CDKL5 Forum12
Dr. Khwaja's extensive experience in rare diseases and drug development makes him well-suited for his role at VectivBio AG, where he is involved in developing innovative treatments for severe rare conditions with high unmet medical needs.12
Highlights
It was with great sadness to hear today of the passing of Professor Mavis Agbandje-McKenna. Professor of Biochemistry and Molecular Biology at the University of Florida, and Director of the Center for Structural Biology, Mavis was a giant in the field of viral structural biology, in particular AAV gene therapy. She was a long-time collaborator, friend, and scientific advisor to Voyager Therapeutics and continued to work closely with our team of talented viral vector engineers. She was honored with the American Society for Gene and Cell Therapy's Outstanding Achievement Award in 2020. We will miss her enormously and send our condolences to her husband, family, and colleagues. #genetherapy
Looking forward to this event in Boston to discuss the latest advances in this exciting and fast-moving field
https://ter.li/9vt8to #conference #innovation
